Previous Close | 5.70 |
Open | 5.60 |
Bid | 5.51 x 1200 |
Ask | 5.59 x 1000 |
Day's Range | 5.26 - 5.68 |
52 Week Range | 3.82 - 10.08 |
Volume | |
Avg. Volume | 35,772 |
Market Cap | 149.249M |
Beta (5Y Monthly) | -0.07 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.63 |
Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.20 |
Subscribe to Yahoo Finance Plus to view Fair Value for FENC
RESEARCH TRIANGLE PARK, N.C., May 23, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that the Company will be participating in upcoming conferences. The management team will also host one-on-one investor meetings at the conferences. Presentation Details: Even
~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~ ~ If Approved by the FDA, PEDMARKTM Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ Company Has Approximately $18.3 Million in Cash and $5 Million of Funded Debt ~ RESEARCH TRIANGLE PARK, N.C., May 12, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM
As inflation keeps climbing, market capitalization – and profits – are sinking at Triangle companies. And economists say it could be just the beginning.